Cargando…

The Feasibility of Immunocryosurgery in the Treatment of Non-Superficial, Facial Basal Cell Carcinoma That Relapsed after Standard Surgical Excision: An Experience Report from Two Centers

In this retrospective, chart review study, we evaluated the feasibility of immunocryosurgery in facial, non-superficial basal cell carcinomas (BCC) that had relapsed after standard surgery. Inclusion criteria were (a) ‘biopsy confirmed relapse of facial BCC’, (b) known ‘calendar year of surgical exc...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaitanis, Georgios, Zampeta, Athanasia, Tsintzou, Panagiota, Fillis, Grigorios, Seretis, Konstantinos, Feldmeyer, Laurence, Bassukas, Ioannis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688977/
https://www.ncbi.nlm.nih.gov/pubmed/36354728
http://dx.doi.org/10.3390/curroncol29110668
_version_ 1784836406628057088
author Gaitanis, Georgios
Zampeta, Athanasia
Tsintzou, Panagiota
Fillis, Grigorios
Seretis, Konstantinos
Feldmeyer, Laurence
Bassukas, Ioannis
author_facet Gaitanis, Georgios
Zampeta, Athanasia
Tsintzou, Panagiota
Fillis, Grigorios
Seretis, Konstantinos
Feldmeyer, Laurence
Bassukas, Ioannis
author_sort Gaitanis, Georgios
collection PubMed
description In this retrospective, chart review study, we evaluated the feasibility of immunocryosurgery in facial, non-superficial basal cell carcinomas (BCC) that had relapsed after standard surgery. Inclusion criteria were (a) ‘biopsy confirmed relapse of facial BCC’, (b) known ‘calendar year of surgical excision(s)’, and (c) ‘relapse within 10 years after the last surgical excision’. Tumors treated from 1 January 2011 to 31 December 2020 with a standard 5-week immunocryosurgery cycle (daily imiquimod application for 5 weeks and a cryosurgery session at day 14) were included. Descriptive statistics, Kaplan–Meier method, and Cox proportional hazards model were calculated with significance at p < 0.05. From the n = 27 BCC evaluated, n = 20 (74.1 ± 8.4%) cleared after one immunocryosurgery cycle. Two of the remaining cases cleared completely after a repeat cycle, one patient favored surgery, and four BCC did not clear despite additional immunocryosurgery cycles (feasibility 81.5 ± 7.5%). Of the 22 tumors with clinical outcome ‘complete clearance with immunocryosurgery’, three BCC relapsed at 9, 28, and 50 months. Overall, the 5–year treatment efficacy rate was 60.2 ± 13.4% (mean follow-up 94.6 ± 15.1 months). In total, 20/27 BCC relapses after surgery (74.1%) were tumor-free at the end of personalized follow-up times (66.7 ± 12.4% tumor free patients at 5-year follow-up). Number of tumor relapses before immunocryosurgery was the single predictor of tumor progression after immunocryosurgery (p = 0.012). Conclusively, immunocryosurgery could be further evaluated as an alternative, definitive treatment of selected facial BCC relapsing after surgery.
format Online
Article
Text
id pubmed-9688977
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96889772022-11-25 The Feasibility of Immunocryosurgery in the Treatment of Non-Superficial, Facial Basal Cell Carcinoma That Relapsed after Standard Surgical Excision: An Experience Report from Two Centers Gaitanis, Georgios Zampeta, Athanasia Tsintzou, Panagiota Fillis, Grigorios Seretis, Konstantinos Feldmeyer, Laurence Bassukas, Ioannis Curr Oncol Article In this retrospective, chart review study, we evaluated the feasibility of immunocryosurgery in facial, non-superficial basal cell carcinomas (BCC) that had relapsed after standard surgery. Inclusion criteria were (a) ‘biopsy confirmed relapse of facial BCC’, (b) known ‘calendar year of surgical excision(s)’, and (c) ‘relapse within 10 years after the last surgical excision’. Tumors treated from 1 January 2011 to 31 December 2020 with a standard 5-week immunocryosurgery cycle (daily imiquimod application for 5 weeks and a cryosurgery session at day 14) were included. Descriptive statistics, Kaplan–Meier method, and Cox proportional hazards model were calculated with significance at p < 0.05. From the n = 27 BCC evaluated, n = 20 (74.1 ± 8.4%) cleared after one immunocryosurgery cycle. Two of the remaining cases cleared completely after a repeat cycle, one patient favored surgery, and four BCC did not clear despite additional immunocryosurgery cycles (feasibility 81.5 ± 7.5%). Of the 22 tumors with clinical outcome ‘complete clearance with immunocryosurgery’, three BCC relapsed at 9, 28, and 50 months. Overall, the 5–year treatment efficacy rate was 60.2 ± 13.4% (mean follow-up 94.6 ± 15.1 months). In total, 20/27 BCC relapses after surgery (74.1%) were tumor-free at the end of personalized follow-up times (66.7 ± 12.4% tumor free patients at 5-year follow-up). Number of tumor relapses before immunocryosurgery was the single predictor of tumor progression after immunocryosurgery (p = 0.012). Conclusively, immunocryosurgery could be further evaluated as an alternative, definitive treatment of selected facial BCC relapsing after surgery. MDPI 2022-11-07 /pmc/articles/PMC9688977/ /pubmed/36354728 http://dx.doi.org/10.3390/curroncol29110668 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gaitanis, Georgios
Zampeta, Athanasia
Tsintzou, Panagiota
Fillis, Grigorios
Seretis, Konstantinos
Feldmeyer, Laurence
Bassukas, Ioannis
The Feasibility of Immunocryosurgery in the Treatment of Non-Superficial, Facial Basal Cell Carcinoma That Relapsed after Standard Surgical Excision: An Experience Report from Two Centers
title The Feasibility of Immunocryosurgery in the Treatment of Non-Superficial, Facial Basal Cell Carcinoma That Relapsed after Standard Surgical Excision: An Experience Report from Two Centers
title_full The Feasibility of Immunocryosurgery in the Treatment of Non-Superficial, Facial Basal Cell Carcinoma That Relapsed after Standard Surgical Excision: An Experience Report from Two Centers
title_fullStr The Feasibility of Immunocryosurgery in the Treatment of Non-Superficial, Facial Basal Cell Carcinoma That Relapsed after Standard Surgical Excision: An Experience Report from Two Centers
title_full_unstemmed The Feasibility of Immunocryosurgery in the Treatment of Non-Superficial, Facial Basal Cell Carcinoma That Relapsed after Standard Surgical Excision: An Experience Report from Two Centers
title_short The Feasibility of Immunocryosurgery in the Treatment of Non-Superficial, Facial Basal Cell Carcinoma That Relapsed after Standard Surgical Excision: An Experience Report from Two Centers
title_sort feasibility of immunocryosurgery in the treatment of non-superficial, facial basal cell carcinoma that relapsed after standard surgical excision: an experience report from two centers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688977/
https://www.ncbi.nlm.nih.gov/pubmed/36354728
http://dx.doi.org/10.3390/curroncol29110668
work_keys_str_mv AT gaitanisgeorgios thefeasibilityofimmunocryosurgeryinthetreatmentofnonsuperficialfacialbasalcellcarcinomathatrelapsedafterstandardsurgicalexcisionanexperiencereportfromtwocenters
AT zampetaathanasia thefeasibilityofimmunocryosurgeryinthetreatmentofnonsuperficialfacialbasalcellcarcinomathatrelapsedafterstandardsurgicalexcisionanexperiencereportfromtwocenters
AT tsintzoupanagiota thefeasibilityofimmunocryosurgeryinthetreatmentofnonsuperficialfacialbasalcellcarcinomathatrelapsedafterstandardsurgicalexcisionanexperiencereportfromtwocenters
AT fillisgrigorios thefeasibilityofimmunocryosurgeryinthetreatmentofnonsuperficialfacialbasalcellcarcinomathatrelapsedafterstandardsurgicalexcisionanexperiencereportfromtwocenters
AT seretiskonstantinos thefeasibilityofimmunocryosurgeryinthetreatmentofnonsuperficialfacialbasalcellcarcinomathatrelapsedafterstandardsurgicalexcisionanexperiencereportfromtwocenters
AT feldmeyerlaurence thefeasibilityofimmunocryosurgeryinthetreatmentofnonsuperficialfacialbasalcellcarcinomathatrelapsedafterstandardsurgicalexcisionanexperiencereportfromtwocenters
AT bassukasioannis thefeasibilityofimmunocryosurgeryinthetreatmentofnonsuperficialfacialbasalcellcarcinomathatrelapsedafterstandardsurgicalexcisionanexperiencereportfromtwocenters
AT gaitanisgeorgios feasibilityofimmunocryosurgeryinthetreatmentofnonsuperficialfacialbasalcellcarcinomathatrelapsedafterstandardsurgicalexcisionanexperiencereportfromtwocenters
AT zampetaathanasia feasibilityofimmunocryosurgeryinthetreatmentofnonsuperficialfacialbasalcellcarcinomathatrelapsedafterstandardsurgicalexcisionanexperiencereportfromtwocenters
AT tsintzoupanagiota feasibilityofimmunocryosurgeryinthetreatmentofnonsuperficialfacialbasalcellcarcinomathatrelapsedafterstandardsurgicalexcisionanexperiencereportfromtwocenters
AT fillisgrigorios feasibilityofimmunocryosurgeryinthetreatmentofnonsuperficialfacialbasalcellcarcinomathatrelapsedafterstandardsurgicalexcisionanexperiencereportfromtwocenters
AT seretiskonstantinos feasibilityofimmunocryosurgeryinthetreatmentofnonsuperficialfacialbasalcellcarcinomathatrelapsedafterstandardsurgicalexcisionanexperiencereportfromtwocenters
AT feldmeyerlaurence feasibilityofimmunocryosurgeryinthetreatmentofnonsuperficialfacialbasalcellcarcinomathatrelapsedafterstandardsurgicalexcisionanexperiencereportfromtwocenters
AT bassukasioannis feasibilityofimmunocryosurgeryinthetreatmentofnonsuperficialfacialbasalcellcarcinomathatrelapsedafterstandardsurgicalexcisionanexperiencereportfromtwocenters